The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success ...
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback